Keywords
Statins
SARS-CoV-2
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe the relationship between COVID-19 and statin treatment in hospitalized patients, according to current studies developed throughout the pandemic. Methods: This is an integrative review, with a search in the PubMed database. The inclusion criteria were the reliability of the obtained data and their conclusions, publications in english, published in the last 2 years (2023 – 2024). Results: Thus, after reading and analysis, 13 articles were selected. Most articles suggest that statins are associated with potential benefits in the treatment of COVID-19 patients, especially concerning the reduction of inflammatory and thromboembolic effects, thereby reducing mortality. However, the results show significant variability among studies, indicating that the current evidence is not yet strong enough to robustly support the hypothesis that statins play a crucial role in reducing disease progression and mortality in COVID-19 patients. Final considerations: Despite the promising use of statins in hospitalized COVID-19 patients, robust clinical evidence is still a lacking. Further clinical research is needed to validate these benefits and establish clear guidelines for the use of statins in the context of the COVID-19 pandemic.
References
AL-SAMKARI H, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood, 2020; 136(4): 489-500.
ALSHAALAN KS, et al. Statin use and clinical outcomes in hospitalized COVID-19 patients: A retrospective analysis in Riyadh, Saudi Arabia. Saudi Med J, 2024; 45(2): 171-178.
APARISI Á, et al. Dyslipidemia and Inflammation as Hallmarks of Oxidative Stress in COVID-19: A Follow-Up Study. Int J Mol Sci., 2022; 23(23): 15350.
BARGE-CABALLERO E, et al. Survival impact of previous statin therapy in patients hospitalized with COVID-19. Med Clin (Engl Ed), 2023; 160(1): 1-9.
CARVALHO DFD, et al. Perfil lipídico e estado nutricional de adolescentes. Revista Brasileira de Epidemiologia, 2007; 10(4): 491-498.
CRIMI E, et al. Beneficial effects of prehospital use of statins in a large United States cohort of hospitalized coronavirus disease 2019 patients. J Cardiovasc Med (Hagerstown), 2023; 24(3): 172-183.
GAITÁN-DUARTE HG, et al. Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. E Clinical Medicine, 2022; 43: 101242.
GÓMEZ-MESA JE, et al. Thrombosis and Coagulopathy in COVID-19. Curr Probl Cardiol., 2021; 46(3): 100742.
HANFF TC, et al. Thrombosis in COVID-19. Am J Hematol, 2020; 95(12): 1578-1589.
HO HV, et al. A Retrospective Cohort Study Assessing the Impact of Statin Therapy on Hospital Length of Stay and Inpatient Mortality in COVID-19 Patients. HCA Healthc J Med, 2023; 4(5): 369-375.
ISMAIL A, et al. Statin Therapy, Inflammation, and Outcomes in Patients Hospitalized for COVID-19: A Prospective Multicenter Cohort Study. Am J Med, 2024; 2-9343(24)506.
IZKHAKOV E, et al. Routine statins use is associated with less adverse outcome in patients above 70 years of age admitted to hospital with COVID-19. BMC Geriatr, 2023; 23(1): 473.
KHAN M, et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules, 2020; 26(1): 39.
KOČAR E, et al. Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications. Biochim Biophys Acta Mol Cell Biol Lipids, 2021; 1866(2): 158849.
LIAO JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol, 2002; 86(1): 5-18.
LIU C, et al. Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19. Front Nutr, 2022; 9: 927092.
LOWENSTEIN CJ e SOLOMON SD. Severe COVID-19 Is a Microvascular Disease. Circulation. 2020; 142(17): 1609-1611.
MARTÍNEZ CJ, et al. Role of statins in clinical evolution of octogenarian patients admitted due to COVID-19. Med Clin (Barc), 2023; 161(4): 147-153.
PARIHAR A, et al. Statins lower calcium-induced oxidative stress in isolated mitochondria. Hum Exp Toxicol, 2012; 31(4): 355-63.
PAWLOS A, et al. COVID-19: Direct and Indirect Mechanisms of Statins. Int J Mol Sci, 2021; 22(8): 4177.
RAY JG. Dyslipidemia, statins, and venous thromboembolism: a potential risk factor and a potential treatment. Curr Opin Pulm Med, 2003; 9(5): 378-84.
REMAP-CAP Investigators, et al. Simvastatin in Critically Ill Patients with Covid-19. N Engl J Med, 2023; 389(25): 2341-2354.
RIVERA AS, et al. Association of statin use with outcomes of patients admitted with COVID-19: an analysis of electronic health records using superlearner. BMC Infect Dis, 2023; 23(1): 115.
RODRIGUEZ-NAVA G, et al. Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study. Crit Care, 2020; 24(1): 429.
RONG Y, et al. Association of antecedent statin use on 30-day, 60-day and 90-day mortality among Mississippi Medicaid beneficiaries diagnosed with COVID-19. BMJ Open, 2023; 13(11): 76195.
SIRTORI CR. The pharmacology of statins. Pharmacol Res, 2014; 88: 3-11.
SOUZA LJ, et al. Prevalence of dyslipidemia and risk factors in Campos dos Goytacazes, in the Brazilian state of Rio de Janeiro. Arq Bras Cardiol, 2003; 81(3): 249-64.
SPERRY MM, et al. Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients. PLoS Comput Biol, 2023; 19(5): 1011050.
VALLIANOU NG, et al. Statins and cancer. Anticancer Agents Med Chem., 2014; 14(5): 706-12.
VARGA Z, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet, 2020; 395(10234): 1417-1418.
VISOS-VARELA I, et al. Outpatient atorvastatin use and severe COVID-19 outcomes: A population-based study. J Med Virol, 2023; 95(7): 28971.
WANG LK, et al. Association of Cardiovascular Medications with Adverse Outcomes in a Matched Analysis of a National Cohort of Patients With COVID-19. Am J Med Open, 2023; 9: 100040.
ZHAO T, et al. Altered Lipid Profile in COVID-19 Patients and Metabolic Reprogramming. Front Microbiol, 2022; 13: 863802.